Compare Stocks: TRVI, CRNX, ALKS, and LQDA

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALKS Alkermes	$49.48 -0.7%	$50.23	$25.17 ▼ $55.67	$8.36B	0.34	1.69 million shs	970,911 shs
CRNX Crinetics Pharmaceuticals	$84.72 0.0%	$66.01	$28.73 ▼ $84.80	$8.98B	0.12	2.61 million shs	3.97 million shs
LQDA Liquidia	$74.33 -4.3%	$79.15	$21.15 ▼ $93.61	$6.66B	0.58	1.69 million shs	1.45 million shs
TRVI Trevi Therapeutics	$18.84 +1.9%	$17.61	$6.93 ▼ $20.22	$2.63B	1.03	1.74 million shs	1.75 million shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALKS Alkermes	-0.74%	+0.55%	-6.15%	+33.80%	+76.02%
CRNX Crinetics Pharmaceuticals	-0.04%	+0.43%	+1.03%	+133.58%	+184.87%
LQDA Liquidia	-4.34%	-15.58%	-7.02%	+20.33%	+168.15%
TRVI Trevi Therapeutics	+1.95%	+5.84%	-1.21%	+35.73%	+152.89%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALKS Alkermes	$49.48 -0.7%	$50.23	$25.17 ▼ $55.67	$8.36B	0.34	1.69 million shs	970,911 shs
CRNX Crinetics Pharmaceuticals	$84.72 0.0%	$66.01	$28.73 ▼ $84.80	$8.98B	0.12	2.61 million shs	3.97 million shs
LQDA Liquidia	$74.33 -4.3%	$79.15	$21.15 ▼ $93.61	$6.66B	0.58	1.69 million shs	1.45 million shs
TRVI Trevi Therapeutics	$18.84 +1.9%	$17.61	$6.93 ▼ $20.22	$2.63B	1.03	1.74 million shs	1.75 million shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALKS Alkermes	-0.74%	+0.55%	-6.15%	+33.80%	+76.02%
CRNX Crinetics Pharmaceuticals	-0.04%	+0.43%	+1.03%	+133.58%	+184.87%
LQDA Liquidia	-4.34%	-15.58%	-7.02%	+20.33%	+168.15%
TRVI Trevi Therapeutics	+1.95%	+5.84%	-1.21%	+35.73%	+152.89%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALKS Alkermes	2.72	Moderate Buy	$54.56	10.27% Upside
CRNX Crinetics Pharmaceuticals	2.24	Hold	$81.00	-4.39% Downside
LQDA Liquidia	2.45	Hold	$98.08	31.96% Upside
TRVI Trevi Therapeutics	3.00	Buy	$27.08	43.75% Upside

Current Analyst Ratings Breakdown

Latest TRVI, CRNX, ALKS, and LQDA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/14/2026	TRVI Trevi Therapeutics	JonesTrading Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$24.00 ➝ $28.00
8/13/2026	LQDA Liquidia	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Strong-Buy	$106.00
8/13/2026	LQDA Liquidia	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$62.00 ➝ $108.00
8/13/2026	LQDA Liquidia	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/13/2026	LQDA Liquidia	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$79.00 ➝ $92.00
8/12/2026	LQDA Liquidia	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$109.00 ➝ $111.00
8/12/2026	LQDA Liquidia	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$70.00 ➝ $110.00
8/12/2026	LQDA Liquidia	Lifesci Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Outperform ➝ Hold	$90.00
8/7/2026	ALKS Alkermes	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold (C)
8/7/2026	TRVI Trevi Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$23.00
8/7/2026	TRVI Trevi Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$24.00 ➝ $25.00

(Data available from 8/19/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALKS Alkermes	$1.67B	4.98	$1.69 per share	29.30	$11.02 per share	4.49
CRNX Crinetics Pharmaceuticals	$7.70M	1,167.05	N/A	N/A	$9.71 per share	8.73
LQDA Liquidia	$158.32M	42.02	N/A	N/A	$0.51 per share	145.75
TRVI Trevi Therapeutics	N/A	N/A	N/A	N/A	$1.43 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALKS Alkermes	$241.66M	$0.38	130.21	206.17	N/A	3.96%	4.15%	2.19%	10/28/2026 (Estimated)
CRNX Crinetics Pharmaceuticals	-$465.32M	-$5.04	N/A	N/A	N/A	-1,189.88%	-44.22%	-39.77%	11/5/2026 (Estimated)
LQDA Liquidia	-$68.92M	$1.37	54.26	16.97	N/A	30.74%	149.65%	36.30%	11/2/2026 (Estimated)
TRVI Trevi Therapeutics	-$42.76M	-$0.34	N/A	N/A	N/A	N/A	-23.59%	-22.64%	N/A

Latest TRVI, CRNX, ALKS, and LQDA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2026	Q2 2026	LQDA Liquidia	$0.7580	$0.74	-$0.0180	$0.74	$168.48 million	$171.68 million
8/6/2026	Q2 2026	TRVI Trevi Therapeutics	-$0.1095	-$0.11	-$0.0005	-$0.11	N/A	N/A
8/3/2026	Q2 2026	CRNX Crinetics Pharmaceuticals	-$1.18	-$1.14	+$0.04	-$1.14	$14.84 million	$25.12 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALKS Alkermes	N/A	N/A	N/A	N/A	N/A
CRNX Crinetics Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
LQDA Liquidia	N/A	N/A	N/A	N/A	N/A
TRVI Trevi Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALKS Alkermes	0.82	2.30	1.85
CRNX Crinetics Pharmaceuticals	N/A	15.57	15.53
LQDA Liquidia	0.63	2.31	2.12
TRVI Trevi Therapeutics	N/A	37.28	37.28

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALKS Alkermes	95.21%
CRNX Crinetics Pharmaceuticals	98.51%
LQDA Liquidia	64.54%
TRVI Trevi Therapeutics	95.76%

Insider Ownership

Company	Insider Ownership
ALKS Alkermes	4.59%
CRNX Crinetics Pharmaceuticals	3.80%
LQDA Liquidia	25.60%
TRVI Trevi Therapeutics	15.39%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALKS Alkermes	2,050	167.76 million	160.06 million	Optionable
CRNX Crinetics Pharmaceuticals	210	106.07 million	102.04 million	Optionable
LQDA Liquidia	50	89.51 million	66.60 million	Optionable
TRVI Trevi Therapeutics	20	142.48 million	120.55 million	Optionable

TRVI, CRNX, ALKS, and LQDA Headlines

Recent News About These Companies

Flputnam Investment Management Co. Makes New $19.36 Million Investment in Trevi Therapeutics, Inc. $TRVI

August 17 at 4:08 AM | marketbeat.com

Trevi Therapeutics (NASDAQ:TRVI) Price Target Raised to $28.00

August 17 at 1:54 AM | americanbankingnews.com

Walleye Capital LLC Purchases Shares of 241,987 Trevi Therapeutics, Inc. $TRVI

August 15, 2026 | marketbeat.com

What is HC Wainwright's Forecast for TRVI FY2026 Earnings?

August 15, 2026 | americanbankingnews.com

JonesTrading Forecasts Strong Price Appreciation for Trevi Therapeutics (NASDAQ:TRVI) Stock

August 14, 2026 | marketbeat.com

HC Wainwright Predicts Lower Earnings for Trevi Therapeutics

August 14, 2026 | americanbankingnews.com

HC Wainwright Issues Pessimistic Estimate for TRVI Earnings

August 13, 2026 | marketbeat.com

Sei Investments Co. Has $933,000 Holdings in Trevi Therapeutics, Inc. $TRVI

August 13, 2026 | marketbeat.com

What is HC Wainwright's Forecast for TRVI FY2030 Earnings?

August 12, 2026 | marketbeat.com

1,525,314 Shares in Trevi Therapeutics, Inc. $TRVI Acquired by Assenagon Asset Management S.A.

August 10, 2026 | marketbeat.com

Trevi Therapeutics (NASDAQ:TRVI) Price Target Raised to $30.00

August 10, 2026 | americanbankingnews.com

Trevi Therapeutics (NASDAQ:TRVI) Announces Earnings Results, Hits Estimates

August 7, 2026 | marketbeat.com

Trevi Therapeutics Q2 Earnings Call Highlights

August 7, 2026 | marketbeat.com

Cantor Fitzgerald Forecasts Strong Price Appreciation for Trevi Therapeutics (NASDAQ:TRVI) Stock

August 7, 2026 | marketbeat.com

Trevi Therapeutics, Inc. (TRVI) Q2 2026 Earnings Call Transcript

August 6, 2026 | seekingalpha.com

Trevi Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates

August 6, 2026 | globenewswire.com

Trevi Therapeutics, Inc. (NASDAQ:TRVI) Receives Average Rating of "Buy" from Analysts

July 31, 2026 | marketbeat.com

Trevi Therapeutics to Report Second Quarter 2026 Financial Results and Provide a Corporate Update on August 6, 2026

July 30, 2026 | globenewswire.com

Trevi Therapeutics (TRVI) to Post Earnings on Thursday

July 30, 2026 | marketbeat.com

Trevi Therapeutics to Participate in Upcoming August Conferences

July 28, 2026 | globenewswire.com

Trevi Therapeutics, Inc. $TRVI Shares Sold by Orbimed Advisors LLC

July 27, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

TRVI, CRNX, ALKS, and LQDA Company Descriptions

Alkermes NASDAQ:ALKS

$49.48 -0.37 (-0.74%)

Closing price 08/18/2026 04:00 PM Eastern

Extended Trading

$49.35 -0.13 (-0.26%)

As of 05:08 AM Eastern

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

Crinetics Pharmaceuticals NASDAQ:CRNX

$84.72 -0.03 (-0.04%)

Closing price 08/18/2026 04:00 PM Eastern

Extended Trading

$84.72 0.00 (0.00%)

As of 08/18/2026 07:56 PM Eastern

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

Liquidia NASDAQ:LQDA

$74.33 -3.37 (-4.34%)

Closing price 08/18/2026 04:00 PM Eastern

Extended Trading

$74.30 -0.03 (-0.04%)

As of 08/18/2026 07:34 PM Eastern

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also offers Remodulin, a treprostinil administered through continuous intravenous and subcutaneous infusion. The company also a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.

Trevi Therapeutics NASDAQ:TRVI

$18.84 +0.36 (+1.95%)

Closing price 08/18/2026 04:00 PM Eastern

Extended Trading

$19.00 +0.16 (+0.82%)

As of 04:37 AM Eastern

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER (CORAL) clinical trial for treatment of chronic cough in patients with IPF; phase 2a Refractory Chronic Cough Improvement Via NAL ER (RIVER) clinical trial for reducing chronic cough in RCC patients; phase 2 clinical trial in patients with pruritus; phase 2b/3 clinical trial in patients with prurigo nodularis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest TRVI, CRNX, ALKS, and LQDA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest TRVI, CRNX, ALKS, and LQDA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

TRVI, CRNX, ALKS, and LQDA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

TRVI, CRNX, ALKS, and LQDA Company Descriptions

Alkermes NASDAQ:ALKS

Crinetics Pharmaceuticals NASDAQ:CRNX

Liquidia NASDAQ:LQDA

Trevi Therapeutics NASDAQ:TRVI

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest TRVI, CRNX, ALKS, and LQDA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest TRVI, CRNX, ALKS, and LQDA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

TRVI, CRNX, ALKS, and LQDA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

TRVI, CRNX, ALKS, and LQDA Company Descriptions

Alkermes NASDAQ:ALKS

Crinetics Pharmaceuticals NASDAQ:CRNX

Liquidia NASDAQ:LQDA

Trevi Therapeutics NASDAQ:TRVI

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools